Ticker brief
ADCT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
7
authors 14d
4
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-24 → 2026-07-01 · now +0.10 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 4 | +0.14 |
| @CrweWorld | C | · | 1 | +0.20 |
| @BioStocks | C | -0.39 | 1 | +0.20 |
| @BiopharmIQ | B | · | 1 | +0.00 |
Recent signals7of 7 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @OzmosiHealth | +0.10 | ADC Therapeutics announced planned Phase 1 DLBCL results in 4Q26. | · | tweet ↗ |
| 2026-06-30 | @BiopharmIQ | +0.00 | Biotech open news list with percentage moves and headlines. | · | tweet ↗ |
| 2026-06-30 | @OzmosiHealth | +0.20 | ADC Therapeutics completes enrollment in LOTIS-7 Phase 1b ZYNLONTA combination trial. | · | tweet ↗ |
| 2026-06-30 | @BioStocks | +0.20 | ADCT completed enrollment in LOTIS-7 Phase 1b trial; data in Q4. | · | tweet ↗ |
| 2026-06-30 | @CrweWorld | +0.20 | ADC Therapeutics completes enrollment in LOTIS-7 Phase 1b trial. | · | tweet ↗ |
| 2026-06-25 | @OzmosiHealth | +0.10 | ADC Therapeutics announces timing for P1 DLBCL results in YE26. | · | tweet ↗ |
| 2026-06-24 | @OzmosiHealth | +0.15 | ADC Therapeutics announces strategic reorganization to support ZYNLONTA growth and regulatory priorities. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.